Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Fires Up Late-Stage R&D After Growth Rekindled in Fourth Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

Nine late-stage products are expected to lead Sanofi’s future evolution into a developer primarily of biologics, including alirocumab for hypercholesterolemia, dupilumab for atopic dermatitis and asthma, and sarilumab for rheumatoid arthritis.

You may also be interested in...

Emerging Markets Earnings Roundup: Sanofi, Teva (Part 7)

Sanofi shows solid growth in emerging markets in the fourth quarter, including an impressive 35.1% gain in China. Teva in transition offers scant detail on emerging markets, but hints larger deals possible in 2014.

Samsung, Merck Look To Take On Sanofi’s Lantus With Latest Deal

In the latest win for Samsung Bioepis, the Korean company will help develop and manufacture a late-stage insulin glargine candidate with Merck.

Genzyme Will Appeal Lemtrada “Complete Response” After FDA Seeks More Trials

Rater-blinded design for multiple sclerosis claim netted an approval in Europe but a rejection by FDA, which was concerned about bias related to open label studies.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts